Ascendis Pharma AS (MEX:ASND1N) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ASND1N Ascendis Pharma AS MEX:ASND1N
43 GF Score
Price MXN4,424.97
! 3 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEX:ASND1N
43GF Score
Ascendis Pharma AS MEX:ASND1N
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Business Description

Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma A/S is a Danish biopharmaceutical company that develops long-acting prodrug therapies using its TransCon technology platform, which is designed to release active drug in a controlled, predictable manner. Its commercial products include Skytrofa (lonapegsomatropin) for pediatric growth hormone deficiency and Yorvipath (palopegteriparatide) for hypoparathyroidism. The pipeline also includes TransCon CNP for achondroplasia and earlier-stage programs in endocrinology and oncology. The company sells primarily in the United States and Europe, with the United States accounting for most revenue, and it also maintains operations in other international markets. Revenue comes from product sales of its commercial therapies, alongside collaboration and licensing arrangements with partners. Ascendis Pharma is headquartered in Copenhagen, Denmark, and is listed on the Nasdaq Global Select Market.
43GF Score

Get the complete analysis for MEX:ASND1N

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,424.97
Price